CN118078827A - Medicine for preventing and treating novel coronavirus and application thereof - Google Patents
Medicine for preventing and treating novel coronavirus and application thereof Download PDFInfo
- Publication number
- CN118078827A CN118078827A CN202410222581.7A CN202410222581A CN118078827A CN 118078827 A CN118078827 A CN 118078827A CN 202410222581 A CN202410222581 A CN 202410222581A CN 118078827 A CN118078827 A CN 118078827A
- Authority
- CN
- China
- Prior art keywords
- novel coronavirus
- compound
- novel
- coronavirus
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 14
- 230000010076 replication Effects 0.000 abstract description 12
- 230000007246 mechanism Effects 0.000 abstract description 4
- 229940126585 therapeutic drug Drugs 0.000 abstract description 3
- 239000003443 antiviral agent Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 102100032959 Alpha-actinin-4 Human genes 0.000 description 22
- 101000797282 Homo sapiens Alpha-actinin-4 Proteins 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 101800001768 Exoribonuclease Proteins 0.000 description 14
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 14
- 101800004575 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 102100031673 Corneodesmosin Human genes 0.000 description 10
- 101710139375 Corneodesmosin Proteins 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- -1 coatings Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 101800000510 Non-structural protein 7 Proteins 0.000 description 6
- 101800000509 Non-structural protein 8 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010015268 Integration Host Factors Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101150092509 Actn gene Proteins 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000007671 third-generation sequencing Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 108010049990 CD13 Antigens Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000012172 direct RNA sequencing Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicine for preventing and treating novel coronavirus and application thereof, belonging to the technical field of application of traditional Chinese medicines. The compound of the invention can target host factors, is used as an excitant of the host factors, inhibits the replication of novel coronaviruses, has broad-spectrum antiviral activity, and plays an important role in preventing and treating the novel coronaviruses. Compared with the existing novel coronavirus therapeutic drugs, the compound has different antiviral action mechanisms, is a beneficial supplement of the existing antiviral drugs, and provides a new choice for the antiviral therapeutic drugs.
Description
Technical Field
The invention belongs to the technical field of application of traditional Chinese medicines, and in particular relates to a medicine for preventing and treating novel coronaviruses and application thereof.
Background
With the subsequent research and development and application of vaccines and small molecular drugs, the currently reported small molecular drugs for treating the new corona, such as Ruidexivir, VV116, nemactetvir/ritonavir and the like, are designed aiming at viruses, but due to the characteristic of continuous mutation of RNA viruses, the novel coronaviruses are continuously mutated in a short period of three years, from initial wild strains to delta strains, to Omikovin, to recent XBB and EG5, and the effect of the vaccines and the small molecular drugs is more and more limited along with the variation of the viruses, so that the development of broad-spectrum antiviral drugs is currently urgently needed.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides a safe, effective and broad-spectrum medicament, and provides application of a compound with the following structure in preparing medicaments for preventing and treating novel coronaviruses:
。
The invention mainly aims at host factors, influences the host factors through the compound (YS-49) with the structure shown above, further inhibits the proliferation of novel coronaviruses, has better broad spectrum and can effectively avoid virus mutation.
Preferably, the novel coronavirus is selected from the novel coronavirus wild strain (WT) or the novel coronavirus ba.5 strain.
Preferably, the medicine for preventing and treating the novel coronavirus comprises a compound or a pharmaceutically acceptable salt of the compound used in the application and a pharmaceutically acceptable auxiliary agent.
Preferably, the pharmaceutically acceptable auxiliary agent comprises one or more of pharmaceutically acceptable carrier, excipient or diluent.
Preferably, the dosage form of the medicine comprises at least one of tablets, capsules, aqueous or oily suspensions, granules, emulsions, oral liquids, injections or powders.
Preferably, the medicament further comprises at least one additional anti-novel coronavirus active ingredient.
Preferably, the concentration of the compound YS-49 in the novel coronavirus prevention and treatment drug is more than or equal to 0.01wt%.
The molecular formula of the compound YS-49 is C 20H19NO2, and the molecular weight is 305.36.
Preferably, the mode of administration of the drug includes at least one of oral, intratumoral, rectal, parenteral injection and topical administration.
The invention breaks away from the conventional micromolecular medicaments designed aiming at viruses, and aims at host factors, thereby achieving the antiviral effect. According to the invention, the host factor actin A4 (ACTN 4) recombinant protein is screened out by using three generations of sequencing, and the ACTN4 is found to have good antiviral effect at the cellular level, and further mechanism research shows that (as shown in figure 1), the ACTN4 is screened out by inhibiting nsp7 and/or nsp8 from combining with nsp12, so that nsp12 combined to a novel coronavirus genome is reduced, further replication of the novel coronavirus is inhibited, and YS-49 is screened out as an agonist of ACTN4 aiming at the ACTN 4. In the process of novel coronavirus replication, nsp7, nsp8 and nsp12 are all minimal replicons, nsp7 and nsp8 bind first, then nsp12 is recruited to form a complex, and then bind to the novel coronavirus RNA to initiate viral replication. However, the novel coronavirus causes reduction of methyltransferase WTAP after infecting cells, resulting in reduced m6A modification on ACTN4 mRNA, which in turn affects RNA degradation and translation, thereby inhibiting ACTN4 expression, so YS-49 acts as an agonist of ACTN4, up-regulates ACTN4 expression, ACTN4 binds to the N-terminus of nsp12, ACTN4 binds to more nsp12 after increasing, and causes ACTN4 to competitively bind to nsp12 with nsp7 and/or nsp8, resulting in reduced nsp12 binding to novel coronarnas, thereby inhibiting viral replication.
Compared with the prior art, the invention has the beneficial effects that:
(1) Aiming at the characteristic that RNA viruses are easy to mutate, the focus of research and development of medicaments is not placed on the viruses, but on host factors, and on the premise that normal vital activities of cells are not influenced, the expression of the host factors is changed to inhibit virus replication, so that the method has better broad spectrum and better avoids the problem of virus mutation.
(2) The invention provides a new idea for drug development and vaccine development in the future.
Drawings
FIG. 1 is a schematic diagram of the mechanism by which ACTN4 regulates SARS-CoV-2 replication.
FIG. 2 is a third generation sequencing flow diagram.
FIG. 3 is a graph depicting that knocking down ACTN4 promotes novel coronavirus replication.
FIG. 4 is a reproduction of novel coronavirus inhibition by overexpressed ACTN 4.
FIG. 5 is a reproduction of YS-49 inhibiting novel coronaviruses.
FIG. 6 is a flow chart of an animal experiment in which YS-49 inhibits novel coronaviruses.
FIG. 7 is a graph of YS-49 inhibiting viral load in lung tissue.
FIG. 8 is a graph of YS-49 inhibiting viral load in brain tissue.
FIG. 9 is a graph showing HE staining results of lung tissue and brain tissue.
Detailed Description
The technical scheme of the invention is further described and illustrated by the following examples. The starting materials used in the examples are all commercially available or prepared by conventional methods.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
The gene sequence of SARS-COV-2 is similar to Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV), which binds to and enters host cells primarily associated with the S protein.
The S protein contains S1 and S2 subunits, wherein the S1 subunit contains a Receptor Binding Domain (RBD) for binding to a cellular receptor, aminopeptidase N (APN); the S2 subunit, which is composed of Fusion Peptide (FP), heptapeptide repeat 1 (HR 1), heptapeptide repeat 2 (HR 2), transmembrane domain (TM) and C-terminal domain (CTD), is responsible for mediating viral fusion and entry.
Related studies have shown that angiotensin converting enzyme ii (ACE 2) is a SARS-COV-2 cell receptor, and that ACE2 is also a receptor for the SARS coronavirus; therefore, the pathway of SARS-COV-2 infection of cells should be similar to that of common coronaviruses.
When a common coronavirus infects cells, a target cell protease cleaves the S protein of the virus, and cleaves the S protein into two subunits S1 and S2, thereby activating the S protein. After the RBD of the S1 subunit binds to the receptor of the host cell, the conformation of the Fusion core formed by the HR1 and HR2 domains in the S2 subunit is changed, and then the Fusion Peptide (FP) of the S2 subunit is exposed and inserted into the target cell membrane, thereby causing membrane Fusion and promoting the virus to enter the cell.
There are three main states in the S protein during membrane fusion, including the pre-fusion natural state, the pre-hairpin intermediate state, and the stable post-fusion hairpin state.
The traditional medicine uses blocking polypeptide (blocking peptide) to prevent cell fusion, but the blocking polypeptide for inhibiting viruses has higher specificity, and different polypeptides are required to be designed aiming at different viruses, if main functional sections are not selected, the polypeptide is overlong, the cost is increased, and the effect is reduced.
In order to solve at least one of the technical problems, the invention provides an application of a compound with the following structure in preparing anti-coronavirus drugs:
。
The compound provided by the invention can excite host factor ACTN4, inhibit the combination of novel coronavirus and nsp12, inhibit the infection activity of coronavirus, has lower cytotoxicity and higher safety, can be applied to the preparation of coronavirus medicaments, reduces coronavirus infection, and has important significance for preventing and treating coronavirus.
Redox is used as a nucleoside analog to stop viral RNA replication by acting on the viral RNA-dependent RNA polymerase (RdRp), and to exert antiviral activity.
The compound of the invention can target host factor ACTN4, activate host factor ACTN4, and the ACTN4 can reduce nsp12 bound to the genome of the novel coronavirus by inhibiting nsp7 from binding to nsp12 and nsp8 from binding to nsp12, thereby inhibiting replication of the novel coronavirus, thus having inhibitory activity on all viruses which complete replication of the novel coronavirus by nsp7 binding to nsp12 and nsp8 binding to nsp12, having good broad spectrum and having important effects on prevention and treatment of coronavirus.
Therefore, the compound has an antiviral action mechanism different from that of the Ruidexivir, and provides a new choice for antiviral therapeutic drugs.
The concentration of WT at 50% of the dose of the compound having the structure as described above for inhibiting cell infection in the present invention is 2.586. Mu.g/mL, and the concentration of BA.5 strain at 50% of the dose of the compound having the structure as described above for inhibiting cell infection in the present invention is 1.170. Mu.g/mL, wherein EC50 means half maximal effect concentration.
The selectivity index SI of the compounds of the formula described above for inhibiting WT infected cells in the present invention is 12.93, where si=tox/AVA, wherein AVA (antiviral activity) denotes EC50, 2.586, TOX (cytocity) denotes CC50 denotes the concentration of the drug at which 50% of the cells undergo a cytotoxic reaction, and is an indicator for measuring the cytotoxicity of the drug, and 33.44.
The selectivity index SI of the compound with the structure shown in the formula above for inhibiting the ba.5 strain from infecting cells is 28.5, wherein si=tox/AVA, AVA (antiviral activity) is EC50, 1.170, TOX (cytoxicity) is the concentration of the drug at which 50% of cells undergo cytotoxicity reaction, and the index for measuring the cytotoxicity of the drug is 33.34.
The invention evaluates the inhibition activity of the compound against novel coronavirus infected cells through the culture of coronaviruses.
In some embodiments, the novel coronavirus is selected from the novel coronavirus wild strain (WT) or the novel coronavirus ba.5 strain.
The invention also provides an anti-novel coronavirus drug, which comprises the compound or the pharmaceutically acceptable salt of the compound used in the application, and pharmaceutically acceptable auxiliary agents.
In particular, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for administration to patients and commensurate with a reasonable benefit/risk ratio.
"Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers compatible with pharmaceutical administration, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) Starches, such as corn starch, potato starch, and substituted or unsubstituted beta-cyclodextrin; (3) Cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) Oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) Polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
The dosage form of the medicament comprises at least one of tablets, capsules, aqueous or oily suspensions, granules, emulsions, oral liquids, injections or powders according to different using modes of the auxiliary agent.
The dosage form and the mode of administration of the compound of the present invention or the pharmaceutical composition thereof are not particularly limited. For different dosage forms of the medicament, the administration can be carried out by selecting a proper administration mode.
Representative modes of administration include, but are not limited to: oral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, e.g., glycerin; (d) Disintegrants, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent, such as paraffin; (f) an absorption accelerator, e.g., a quaternary amine compound; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) an adsorbent, for example, kaolin; and (i) a lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents. Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances. In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Such as suspensions, may contain suspending agents as, for example, particularly ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms for topical administration include ointments, powders, patches, sprays and inhalants. Is prepared by mixing the active ingredient under aseptic condition with pharmaceutically acceptable carrier and any preservative, buffer or propellant as required.
Embodiments of the present invention will be described in detail below with reference to examples.
Example 1
Three-generation sequencing assay
The flow of the third generation sequencing is shown in FIG. 2: extracting 1 mg total RNA from SARS-CoV-2 infected A549-ACE2 (provided by the Chinese academy of sciences 'Wuhan virus) and Huh7 cells (human hepatoma cells provided by the Chinese academy of sciences' Wuhan virus) and purifying with Oligo (dT) kit; RNA sample libraries were then prepared according to Oxford Nanopore DRS instructions and loaded onto FLO-MIN106D sequencing chips, followed by 48h sequencing run on a MinION device (Oxford Nanopore Technologies). The method comprises the following specific steps:
MESSENGER RNA (mRNA) purification:
(2) Incubating the 1.5. 1.5 mL ribozymal EP tube of step (1) with 100 uL RNA solution in a constant temperature metal bath at 65 ℃ for 2 min to disrupt RNA secondary structure;
(3) 200 mu L of Dynabeads magnetic beads (magnetic beads) resuspended by 1 mg are added into a new 1.5 mL non-ribozyme EP tube, the EP tube is placed on a magnetic rack for standing for 30 s after being uniformly mixed, the supernatant is discarded, and the EP tube is reserved;
(4) Then adding 100 mu L of Binding Buffer into the 1.5 mL non-ribozyme EP tube containing the magnetic beads, uniformly mixing and re-suspending, placing the mixture on a magnetic frame after balancing the magnetic beads, standing for 30: 30 s until the solution is clarified, discarding the supernatant, and reserving the EP tube;
(5) Adding 100 mu L of Binding Buffer re-suspending magnetic beads into the 1.5 mL non-ribozyme EP tube in the step (4), adding 100 mu L of the solution containing 75 mu g of RNA prepared in the step (1), thoroughly mixing, placing the EP tube on a rotary shaking table at room temperature, and incubating for 5 min;
(6) Placing the 1.5 mL non-ribozyme EP tube containing the solution and the magnetic beads in the step (5) on a magnetic rack until the solution is clear, discarding the supernatant, and reserving the EP tube;
(7) Adding 200 mu L Washing Buffer B into the 1.5 mL non-ribozyme EP tube in the step (6), uniformly mixing and re-suspending, placing the mixture on a magnetic rack after balancing magnetic beads, standing for 30 s until the solution is clear, discarding the supernatant, and then repeating the step (7) for one time to reserve the EP tube;
(8) Adding 10 mu L of an addition Buffer into the 1.5 mL non-ribozyme EP tube in the step (7) and incubating for 2 min at 65 ℃ on a constant temperature metal bath, immediately placing the EP tube on a magnetic rack, and standing for 30 s until the solution is clear;
(9) Transferring the supernatant obtained in the step (8) into a brand new 1.5 mL non-ribozyme EP tube for later use.
Library construction:
(1) In a 0.2 mL PCR tube, the following components : 3.0 μL NEB Next Quick Ligation Reaction Buffer 9.0 μL RNA 0.5 μL RNA CS (RCS), 1.0 μL RT Adapter (RTA),1.5 μL T4 DNA Ligase, were added and incubated at room temperature for 10. 10 min;
(2) Preparing the following components of 9.0 mu L of nucleic-FREE WATER,2.0 mu L of 10 mmol/L dNTPs,8.0 mu L of 5 x first-strand buffer and 4.0 mu L of 0.1M DTT, adding the mixed solution into 0.2 mL PCR tube, and uniformly mixing;
(3) Adding 2 mu L of SuperScript III REVERSE TRANSCRIPTASE, uniformly mixing, incubating at 50 ℃ in a constant temperature metal bath for 5min, and incubating at 70 ℃ in the constant temperature metal bath for 10min to inactivate reverse transcriptase;
(4) Transferring the reverse transcription product into a 1.5 mL EP tube, adding 72 mu L of resuspended RNA Clean XP beads, uniformly mixing, and incubating at room temperature for 5 min;
(5) Adding 150 μl of precooled 70% ethanol, mixing, and discarding supernatant;
(6) After adding 20 μl NF H 2 O and incubating at room temperature for 5: 5min, the solution was placed on a magnetic rack and transferred to a new EP tube;
(7) In a new 1.5 mL Eppendorf DNA LoBind tube, the following components :20.0 μL Reverse-transcribed RNA,8.0 μL NEB Next Quick Ligation Reaction Buffer,6.0 μL RNA Adapter,3.0 μL Nuclease-free water,3.0 μL T4 DNA Ligase Mix, were added in sequence and incubated at room temperature for 10 min;
(8) Adding 40 mu L RNACLEAN XP beads, uniformly mixing, and incubating at room temperature for 5 min;
(9) Placing the EP tube on a magnetic rack, standing until the solution is clear, discarding the supernatant, adding 150 mu L Wash Buffer for washing twice, and discarding the supernatant;
(10) Adding 21 mu L of an absorption Buffer to dissolve the precipitate, and incubating for 10min at room temperature;
(11) The EP tube was placed on a magnetic rack and left to settle until the solution was clear and the liquid transferred to a new 1.5 mL Eppendorf DNA LoBind tube.
Sample treatment of the machine: RNA sequencing was performed on the samples prepared as described above using Nanppore DIRECT RNA sequencing (SQK-RNA 002).
By third generation sequencing, it was found that there was one down-regulating host factor ACTN4 in Huh7 cells and a549-ACE2 cells, as shown in fig. 3.
Cell lines for knocking down (as shown in FIG. 3) and over expressing (as shown in FIG. 4) ACTN4 are constructed in Huh7 cells, then WT and BA.5 strains are infected respectively, protein and RNA samples are collected after 48 h, the change condition of viral protein N protein is detected by Western blot experiment, and the change condition of viral protein N protein and S protein is detected by RT-qPCR respectively. As can be seen from fig. 3, protein levels and RNA levels of viral N protein were up-regulated and RNA levels of S protein were up-regulated after ACTN4 knockdown; as can be seen from FIG. 4, both protein and RNA levels of the toxic N protein were down-regulated and RNA levels of the S protein were down-regulated after over-expression of ACTN 4.
As can be seen from FIGS. 3 and 4, ACTN4 is effective in inhibiting replication of the novel coronavirus wild-type strain and BA.5 strain.
Example 2
Cell experiments for YS-49 inhibiting novel coronavirus replication
3 Mug/ml, 6 mug/ml and 18 mug/ml of YS-49 (purchased from Selleck company) solution are respectively prepared by dimethyl sulfoxide (DMSO), after Huh7 cells are respectively treated by YS-49 with different concentrations, WT and BA.5 are infected, protein and RNA samples are collected after 48 hours, the change condition of ACTN4 and virus protein N is detected by Western blot experiment, and the change condition of virus protein N and virus protein S is respectively detected by RT-qPCR.
As can be seen from FIG. 5, after different concentrations of YS-49 were added, the protein level of ACTN4 was up-regulated, the protein level and RNA level of viral protein N were down-regulated, and the RNA level of S protein was also down-regulated, demonstrating that YS-49 effectively inhibits replication of novel coronavirus wild-type strains and BA.5 strains.
Example 3
Animal experiment for YS-49 inhibiting novel coronavirus replication
The experimental procedure is shown in fig. 6: healthy laboratory mice with similar body weights were respectively subjected to gastric lavage administration on the day before and the second day after infection with the novel coronavirus, dissected on the fifth day of infection with the novel coronavirus, and examined for viral loads in lung and brain tissues, respectively (fig. 7 and 8), and observed for tissue lesions with HE staining (fig. 9).
As can be seen from FIGS. 7 and 8, YS-49 has a better effect of inhibiting viral replication than the control group; it can also be seen in FIG. 9 that the extent of lesions in the lung and brain tissues after YS-49 treatment was significantly reduced compared to the control group.
It should be understood that the above examples are only for illustrating the present application and are not intended to limit the scope of the present application. Furthermore, it should be understood that various changes and modifications can be made by one skilled in the art after reading the teachings of the present application, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Claims (8)
1. The application of a compound with the structure shown as the following in preparing a medicament for preventing and treating novel coronavirus:
。
2. the use according to claim 1, wherein the concentration of said compound in the preparation of a medicament for the control of novel coronaviruses is not less than 0.01% by weight.
3. The use according to claim 1, wherein said novel coronavirus comprises a novel coronavirus wild strain (WT) or a novel coronavirus ba.5 strain.
4. The use according to claim 1, wherein the medicament for controlling novel coronaviruses comprises a compound or a pharmaceutically acceptable salt of a compound used in the above application, and a pharmaceutically acceptable adjuvant.
5. The use according to claim 1, wherein the pharmaceutically acceptable adjuvant comprises one or more of a pharmaceutically acceptable carrier, excipient or diluent.
6. The use according to claim 1, wherein the pharmaceutical dosage form comprises at least one of a tablet, a capsule, an aqueous or oily suspension, a granule, an emulsion, an oral liquid, an injection or a powder.
7. The use according to claim 1, wherein the medicament further comprises at least one additional anti-coronavirus active ingredient.
8. The use of claim 1, wherein said medicament is administered by at least one of oral, intratumoral, rectal, parenteral injection and topical administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410222581.7A CN118078827A (en) | 2024-02-28 | 2024-02-28 | Medicine for preventing and treating novel coronavirus and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410222581.7A CN118078827A (en) | 2024-02-28 | 2024-02-28 | Medicine for preventing and treating novel coronavirus and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118078827A true CN118078827A (en) | 2024-05-28 |
Family
ID=91157337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410222581.7A Pending CN118078827A (en) | 2024-02-28 | 2024-02-28 | Medicine for preventing and treating novel coronavirus and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118078827A (en) |
-
2024
- 2024-02-28 CN CN202410222581.7A patent/CN118078827A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080075695A1 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
CN114796177B (en) | Anti-coronavirus medicine and application | |
EP2694087B1 (en) | Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases | |
WO2010053942A1 (en) | Methods for treating hepatitis c virus infection | |
WO2020259706A1 (en) | Use of amlexanox in preparing anti-hepatitis virus drug | |
CN118078827A (en) | Medicine for preventing and treating novel coronavirus and application thereof | |
CN118121605A (en) | Application of norlinderane in prevention and treatment of novel coronavirus | |
KR102517456B1 (en) | Antiviral composition comprising fibroblast growth factor 11 as an active ingredient | |
CN114762694B (en) | Use of oligosaccharide transferase inhibitors for the prevention and/or treatment of novel coronavirus infections | |
AU2011223945B2 (en) | Compositions and methods for treating viral diseases | |
CN110812472B (en) | Application of E3 ubiquitin ligase stub1 in inhibiting replication of hepatitis B virus | |
KR20230037486A (en) | virus suppression | |
CN113502288A (en) | Antisense oligonucleotide and application thereof in inhibiting new coronavirus | |
CN115884770A (en) | Combined medicine for treating coronavirus infection and treatment method | |
WO2004108151A1 (en) | Inhibition of sars coronavirus infection with clinically approved antiviral drugs | |
CN113533723B (en) | Marker of HIV and/or SIV infected cells and application thereof | |
US20230119764A1 (en) | Application of dimethyl berbamine compound in inhibition of sars-cov-2 | |
Zhang et al. | Drugs actively being investigated for use in COVID-19 | |
KR102259058B1 (en) | Pharmaceutical composition for preventing and treating tuberculosis disease comprising Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 inhibitor as effective component | |
JP2020513232A (en) | Detection method of glucose metabolism abnormality and prevention and treatment | |
CHAKRABORTY et al. | Remdesivir---Overview of the most debatable Antiviral of Recent Times | |
TWI620933B (en) | Method of detecting carbohydrate metabolism disorder and the prevention and treatment | |
WO2021224234A1 (en) | Antiviral use of cilengitide | |
CN117224548A (en) | Application of diltiazem hydrochloride in preparation of medicines for resisting porcine respiratory and reproductive disorder syndrome virus | |
CN113662943A (en) | Use of tyrosine kinase AXL inhibitors for the prevention or treatment of coronavirus infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |